Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Investing Activities: 2016-2025

Historic Cash from Investing Activities for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to -$77,000.

  • Akebia Therapeutics' Cash from Investing Activities fell 3750.00% to -$77,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$51,000, marking a year-over-year decrease of 100.26%. This contributed to the annual value of -$33,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Cash from Investing Activities is -$77,000, which was up 38.89% from -$126,000 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Cash from Investing Activities ranged from a high of $20.0 million in Q2 2021 and a low of -$126,000 during Q2 2025.
  • Moreover, its 2-year median value for Cash from Investing Activities was -$15,500 (2024), whereas its average is -$13,667.
  • As far as peak fluctuations go, Akebia Therapeutics' Cash from Investing Activities soared by 8,039.18% in 2021, and later crashed by 3,750.00% in 2025.
  • Akebia Therapeutics' Cash from Investing Activities (Quarterly) stood at $20.0 million in 2021, then slumped by 100.57% to -$114,000 in 2022, then reached -$2,000 in 2024, then plummeted by 3,750.00% to -$77,000 in 2025.
  • Its Cash from Investing Activities was -$77,000 in Q3 2025, compared to -$126,000 in Q2 2025 and $154,000 in Q1 2025.